We analyzed the properties of tetracenomycin C (TcmC)-nonproducing mutants of Streptomyces glaucescens to establish the nature of pathway intermediates and to provide some information about the genetics of antitumor anthracycline antibiotic production. Using cosynthesis properties and metabolite accumulation data, we classified a collection of 34 TcmC-nonproducing strains into seven different groups. From this information, we deduced the positions of the tcm tnutations in relation to a hj pothetical TcmC biosynthetic pathway and suggest which pathway enzymes are affected by the different mutations.
microtiter (plug) plates and the R2YENG mhedium of Hintermann (G. Hintermann, Ph.D. thesis, ETH, Zurich, Switzerland, 1983) but without agar for antibiotic metabolite production by growth in liquid cultures. Bioassays for antibiotic activity were done in ML medium, which is LB mediutn (5) containing NaCl (10 g/liter).
Isolation of TcmC-mutant strains. For the isolation of TcmC-nonproducing (TcmC-) mutant strains, mutagenesis of 107 to 109 spores of S. glaucescens GLA.0 or GLA.567 was carried out by one of the following procedures: treatment with N-methyl-N'-nitro-N-nitrosoguanidine (NTG; Sigma Chemical Co., St. Louis, Mo.) by the method of Delic et al. (6) or treatment with diethyl sulfate (DES; Sigma) or with UV light by the method of Hopwood (10) or Weber et al. (19) . UV light mutagenesis was carried out in the dark to prevent photorepair of DNA lesions, which is known to occur in S. glaucescens (1) . The frequency of tcmC-mutant formation following single mutagenic treatments was ca. 0.05%. The frequency was increased to 0.4% when pairwise combinations of the three mutagens were used, e.g., spores obtained from the <50% survivor population from the first mutagenic treatment (NTG or DES) were combined and treated with a second mutagen (NTG, DES, or UV light). In both cases, colonies from the 1 to 0.001% survivor population were assayed for antibiotic activity as described below.
Colonies grown from single spores surviving mutagenesis and having a normal morphology were picked to HickeyTresner master plates and R2YE plug plates, and the plates were incubated at 30°C for 3 to 4 days. Plugs from the microtiter plates were transferred to bioassay dishes (13 by 9 in. [ca. 33.0 by 22.9 cm]) containing ML medium seeded with ca. 104 spores of S. coelicolor Mlll per ml, and the dishes were incubated overnight at 30'C. TcmC-strains were identified by the lack of zones of Mlll growth inhibition.
Nonproducing colonies were streaked from both the original master and plug plate colonies onto separate Hickey-Tresner plates to isolate single colonies. After sporulatiot, six colonies from each of these plates were transferred to a new set of master and plug plates. After incubation as before, the mutant strains were re-bioassayed. This was done to ensure the genetic homogeneity and stability of the TcmC-phenotype. Two single colonies then were chosen to prepare spore preparations in 20% glycerol by standard methods (11) for storage at -20°C (short term) or -80°C (long term) and to test the stability of the TcmC-phenotype after more than ten serial transfers on solid or in liquid growth media. 20 ,Jl of a dense spore suspension) of tcmC mutant type strains were inoculated into 5 ml of R2YENG medium in a pairwise fashion, and the cultures were grown in a rotary shaker as described above. Metabolite and antibiotic production assays of these cultures were then done as described above.
(b) Precursor feeding method. Cultures (5 ml) of tcmC mutant type strains were grown in R2YENG medium for 2 days as described above. Aliquots (100 pl) of extracts prepared from another or the same class of tcmC mutant (see below) were added, and the cultures were grown for another 2 days. They then were extracted with ethyl acetate and assayed for metabolite and antibiotic production as described above. The extracts added to the cultures were prepared from 50-ml cultures of TcmC-strains which had been grown for 3 to 4 days and extracted with 25 ml of ethyl acetate. The ethyl acetate extracts were evaporated to dryness on a rotary flash evaporator at <30°C, and the residues were then dissolved in 2 ml of dimethyl sulfoxide prior to addition to the 5-ml cultures.
In both methods, the production of TcmC or another TcmC pathway metabolite that was not produced by either mutant strain alone was interpreted as positive cosynthesis. Cosynthesis was observed in the mixed-culture method but not in the precursor feeding method with a few strain combinations, a result which may have been due to the decomposition of unstable metabolites during preparation of the ethyl acetate extracts. The cosynthesis behavior of all type I strains was tested with type strains from each of the other categories, but among the six other categories of tcmC mutants listed in Table 1 , only the type strains indicated were tested for cosynthesis. RESULTS Our ability to identify strains bearing mutations affecting the production of TcmC by S. glaucescens directly was predicated on the report by Weber et al. (21; J. Siebers, Ph.D. dissertation, University of Gottingen, Gottingen, Federal Republic of Germany, 1979) about the occurrence of several metabolites in the wild-type GLA.0 strain that were structurally related to compound 6 (Fig; 1) . Since compounds 4 and 5 and compounds similar to compounds 2 and 3 are likely to be intermediates of the TcmC biosynthetic pathway, we expected that tcm mutations in strains which were identified as TcmC-by their lack of antibiotic activity would cause the accumulation of such metabolites or shunt products derived from them. Consequently, to prepare a collection of TcmC-strains, we subjected spores of strain GLA.0 to three different mutagenic treatments (see Materials and Methods) and then screened the surviving colonies for ones that had a wild-type morphology and level of resistance to TcmC and did not inhibit the growth of S. coelicolor Mlll. Although TcmC inhibits the growth of several Strepto,nyces spp. (20) , strain Mlll is streptomycin resistant, and thus its growth is not inhibited by the 5'-hydroxystreptomycin which S. glaucescens also produces (17) . We eventually acquired 34 TcmC-strains (Table 1) Table 2 .
Cosynthesis (7, 16) and biotransformation experiments were done with the type strains identified in Table 1 formation) methods (see Materials and Methods). The latter method was the principal way that we were able to distinguish between converter and secretor strains and order the tcm mutations, since the extract prepared from a secretor strain will result in the cosynthesis of TcmC only when added to a culture of a converter strain that has a tcm mutation blocking some step preceding the point at which the secreted metabolite enters the TcmC pathway.
On the basis of the above-described criteria, the data in Table 2 Fig. 2 of the accompanying paper [23] and Table 2 ), it appears that type II and IV mutants cannot add a methyl group to the 3 position and the 8 position, respectively, of TcmC biosynthetic pathway intermediates. Consequently, on the basis of the relative positions of the blocks caused by tcmIl and temlV mutations, methylation of the C-3 hydroxyl group appears to preceed methylation of the C-8 hydroxyl group in the TcmC biosynthetic pathway.
Type III mutants cosynthesized TcmC with all but the type Ic mutant and acted as secretor strains towards type Ia, Ib, Id, IV, and VI mutants but not towards type II, V, or VII mutants. Therefore, the temIII mutation must block TcmC biosynthesis beyond the points affected by the temI, temlV, and tcmVI mutations. Since type III mutants accumulated TcmA2 (compound 5), they must not be able to hydroxylate or oxidize positions 4, 4a, and 12a of compound 5.
Finally, the type VII mutant cosynthesized TcmC with all other temC mutants and acted as a secretor strain towards type Ia, Ib, Id, II, IV, V, and VI mutants but not towards type Ic and III mutants. Since the type VII mutant accumulated tetracenomycin Dl (TcmDl) (compound 2) and tetracenomycin E (TcmE) (compound 13 in Fig. 2 of the accompanying paper [23] ), which requires 0-methylation of the C-9 carboxyl group to form TcmA2, it should not act as a secretor strain towards type III mutants, a result which was observed. Conversely, type III mutants should act as secretor strains towards the type VII mutant but did not, a result which is an anomaly. Thus, although we believe that the temVII mutation affects TcmC biosynthesis between the points defined by the temII or temV and tcmIII mutations (see below), an alternate position for the tcmIII mutation preceding that of the temVII mutation (and together with the tcmII and temV mutations) is possible.
On the basis of the foregoing data, we conclude that the most probable order of nine of the tcm mutations in relation to the TcmC biosynthetic pathway is as follows:
We are uncertain about the position of the temlc mutation; therefore, it is not included in the above diagram.
DISCUSSION
TcmC-mutants were isolated at a significant frequency only after the induction of tem mutations by treatment of strains GLA.0 and GLA.567 with UV light, NTG, or DES, singly or in pairwise combinations. During the course of our work, we did not find any spontaneously formed temC mutants, although we did not examine this possibility in an experiment designed to test it directly. Consequently, the tem genes are not easily mutable, and the TcmC-phenotype appears to be stable. This behavior is different from that of the genes governing two other pathways in S. glaucescens, the production of melanin and resistance to 5'-hydroxystreptomycin. Hutter and co-workers have observed that these two characteristics are very unstable (4, 15, 17) and that their loss is in part due to DNA deletions (8, 9) .
The properties of the temC mutants listed in Tables 1 and  2 indicate that all of these 34 strains are blocked in the formation of TcmC at specific points in its biosynthetic pathway. None of these mutant strains had an altered growth rate or colony morphology or any change in the level of resistance to TcmC; therefore, their lack of TcmC produc- tion was not due to pleiotropic effects of mutations in the genes governing the developmental biology of S. glaucescens or the self-resistance that must go hand-in-hand with TcmC production. Furthermore, none of these mutant strains reverted to the TcmC + phenotype after more than 10 serial transfers, indicating that they contained relatively stable tcm mutations.
Several types of tcmC mutants accumulated metabolites structurally related to TcmC and were able to convert some of these compounds to TcmC in the precursor feeding experiments. We used this information (23) to construct a hypothetical biosynthetic pathway for TcmC (Fig. 2) . Using a polyketide origin (2) of TcmC (compound 6) as the basis for our hypothesis, we imagine that a decapolyketide (compound 14) is made from acetate and malonate and then is cyclized to the 12-naphthacenone, TcmF (compound 15). This compound is then converted to TcmA2 (compound 5)
by three different 0-methylation reactions. We cannot be completely certain about the sequence of these methylation reactions, even though, as deduced above, we favor the C-3 hydroxyl --C-8 hydroxyl -* C-9 carboxyl sequence, because the type II, IV, and VII mutants accumulated compounds in which the phenolic hydroxyl group(s) was not methylated but the carboxyl group was and vice versa. (For instance, if only the favored 0-methylation sequence occurred, then we should have found metabolites in which only the C-3 or C-8 hydroxyl group was methylated but not ones in which the C-9 carboxyl group was methylated and the C-3 or C-8 hydroxyl group was unmethylated.) Furthermore, the position of the tcmVII mutation in the TcmC biosynthetic pathway is most consistent with methylation of the phenolic hydroxyl groups occurring before methylation of the C-9 carboxyl group. In contrast, it is clear that TcmC must come from TcmA2 by oxidation and hydration reactions, despite the inability of the type VII mutant to convert TcmA2 to TcmC. However, it is important to realize that the exact order of events in this pathway must remain uncertain until we obtain some information about the properties of the pathway enzymes. Until that time, we cannot know the real reason why the type II, III, IV, and VII mutants accumulated certain metabolites. For example, it is not clear why the wild-type and type VII mutant strains accumulated compound 2, which lacks the C-9 carboxyl group needed for the formation of compound 6. We also must recognize that these metabolites can be main pathway intermediates or shunt products derived from alternate metabolic pathways or from the action of relatively nonspecific enzymes of secondary metabolism in S. glaucescens.
It is of some interest, in relation to the mechanism of action of TcmC as an antibiotic, that only one of the compounds accumulated by the tcmC mutants was able to inhibit the growth of S. coelicolor Mlll. This metabolite was compound 12, which lacks the C-8 methyl group found in compound 6 . It has a weaker activity than TcmC, since the strain producing it was found on the basis of a TcmCphenotype.
On the basis of the metabolites accumulated by different types of TcmC-strains and on the order of tcm mutations deduced above from the results of the cosynthesis experiments, the following deductions can be made about the effects of certain tcm mutations on the biosynthesis of TcmC. The tcmla and tcmlb mutations must block the formation of compound 14 or 15 (Fig. 2) because they prevent the formation of any pathway intermediates. Perhaps these mutations reside in the gene encoding the formation of the putative decapolyketide synthase or cyclase, but this must remain uncertain until assays for these enzymes are developed. Furthermore, at this time we cannot offer a VOL. 167. 1986 on August 27, 2017 by guest http://jb.asm.org/ Downloaded from reason for the different cosynthesis behavior of type Ia and lb mutants. The tcmII, tcm-IV, tcm-V, and tcm-VII mutations must block the three different methylation reactions leading to compound 5, since these four types of mutations cause the accumulation of demethylated pathway intermediates or their shunt metabolites. The tcmIII mutations must block the conversion of compound 5 to compound 6 for the reasons suggested earlier, since compound 5 is accumulated by these strains. Finally, the ability of the type Ic mutant to cosynthesize TcmC only with the type VII mutant suggests that the tcmIc mutation affects more than one step in the biosynthetic pathway. A mutation in a gene that regulates the expression of several other tcm genes or the activity of pathway enzymes is an attractive possibility, as is also true for the tcmld mutations, which reduce the rate of TcmC production. We cannot deduce the exact reasons for the effects of these two mutations from the available data, however.
We have used this collection of strains having specific blocks in the TcmC biosynthetic pathway to clone DNA which complements all 10 of the tcm mutations and to map representative tcm genes in relation to other markers on the S. glaucescens linkage map (1; H. Motamedi, E. WendtPinekowski, and C. R. Hutchinson, unpublished data). Therefore, the availability of tcm genes and knowledge about the chemistry of TcmC biosynthetic pathway metabolites will facilitate studies of the enzymology and regulation of TcmC production and attempts to construct hybrid anthracycline antibiotics by using the strategy pioneered by Hopwood and co-workers (12) .
